Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Historical Holders from Q2 2021 to Q3 2025

Symbol
VERV
CUSIP
92539P101
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
89.6M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
94.3K
Holdings value
$1.13M
% of all portfolios
0%
Grand Portfolio weight change
-0.001%
Number of holders
4
Number of sells
-165
Average Value change %
0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Pentwater Capital Management LP 7.5% $74.8M 6.72M Pentwater Capital Management LP Jun 30, 2025
BlackRock, Inc. 7% $18.3M 6.18M BlackRock, Inc. Mar 31, 2025
MILLENNIUM MANAGEMENT LLC 4.9% +6% $12.9M $1.21M 4.33M +10.4% Millennium Management LLC Apr 22, 2025
STATE STREET CORP 3.8% $9.61M 3.24M STATE STREET CORPORATION Dec 31, 2024

Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 94.3K $1.13M -$812M $11.27 4
2025 Q2 72.9M $819M +$44.4M $11.23 172
2025 Q1 80.8M $369M +$7.86M $4.57 189
2024 Q4 78.6M $444M +$18.8M $5.64 162
2024 Q3 75.2M $364M -$7.27M $4.84 169
2024 Q2 76.1M $371M +$9.87M $4.88 161
2024 Q1 4.39M $58.2M -$560K $13.28 17
2023 Q4 112K $1.57M -$353K $13.94 3
2023 Q3 63.8M $846M +$19.5M $13.26 127
2023 Q2 61.7M $1.16B -$20.1M $18.75 115
2023 Q1 63.3M $912M +$3.33M $14.42 122
2022 Q4 62.6M $1.21B +$9.15M $19.35 117
2022 Q3 60.4M $2.07B +$501M $34.35 119
2022 Q2 45.4M $693M -$28.2M $15.28 92
2022 Q1 46.6M $1.06B +$20M $22.82 91
2021 Q4 45.1M $1.66B +$125M $36.87 87
2021 Q3 38.7M $1.81B +$24.1M $47.00 72
2021 Q2 37.7M $2.25B +$2.25B $60.25 69